• Human TIGIT protein (Recombinant) (C-His & Avi) {Biotin} (STJP002034)
  • Human TIGIT protein (Recombinant) (C-His & Avi) {Biotin} (STJP002034)
  • Human TIGIT protein (Recombinant) (C-His & Avi) {Biotin} (STJP002034)

Human TIGIT protein (Recombinant) (C-His & Avi) {Biotin} (STJP002034)

SKU:
STJP002034-100

Shipping:
Free Shipping
Current Stock:
Host: HEK293 cells
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Recombinant-Human TIGIT-C-His & Avi protein was developed from hek293 cells and has a target region of C-His & Avi. For use in research applications.
Conjugation: Biotin
Formulation: Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4.
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: TIGIT
Gene ID: 201633
Uniprot ID: TIGIT_HUMAN
Immunogen Region: Met22-Pro141
Immunogen: Biotinylated Recombinant Human TIGIT Protein is produced by Expi293 expression system. The target protein is expressed with sequence (Met22-Pro141) of Human TIGIT fused with a His tag and Avi tag at the C-terminal.
Function Binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells.
Protein Name T-Cell Immunoreceptor With Ig And Itim Domains
V-Set And Immunoglobulin Domain-Containing Protein 9
V-Set And Transmembrane Domain-Containing Protein 3
Cellular Localisation Cell Membrane
Single-Pass Type I Membrane Protein
Alternative Protein Names T-Cell Immunoreceptor With Ig And Itim Domains protein
V-Set And Immunoglobulin Domain-Containing Protein 9 protein
V-Set And Transmembrane Domain-Containing Protein 3 protein
TIGIT protein
VSIG9 protein
VSTM3 protein

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance